🇺🇸 FDA

Company profile · Sponsor

Agios

Agios Netherlands B.V.

AGIO · NYSE pharma CAMBRIDGE, MA, EU
Pipeline
24
Drugs
3
Patents
8

Quick answer

Agios (AGIO) is a pharma company. headquartered in CAMBRIDGE, MA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker AGIO
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, EU
SEC CIK 0001439222

Pipeline (24)

Search pipeline →

  1. AG-348

    Agios

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    2 trials

  2. Mitapivat

    Agios

    Non-Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  3. Mitapivat

    Agios

    Sickle Cell Disease

    phase 3 small molecule active

    2 trials

  4. Mitapivat

    Agios

    Pediatric Pyruvate Kinase Deficiency

    phase 3 small molecule active

    2 trials

  5. Mitapivat Matched Placebo

    Agios

    Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  6. Placebo

    Agios

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    1 trial

  7. Placebo Matching Mitapivat

    Agios

    Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  8. Placebo Matching Mitapivat

    Agios

    Non-Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  9. AG-120

    Agios

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  10. AG-348

    Agios

    Thalassemia

    phase 2 small molecule active

    1 trial

  11. Enasidenib

    Agios

    Hematologic Neoplasms

    phase 2 small molecule completed

    1 trial

  12. Mitapivat

    Agios

    Anemia

    phase 2 small molecule active

    1 trial

  13. Tebapivat

    Agios

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  14. Tebapivat

    Agios

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  15. ivosidenib and nivolumab

    Agios

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  16. AG-120 (Ivosidenib)

    Agios

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  17. AG-181

    Agios

    Phenylketonuria

    phase 1 small molecule active

    1 trial

  18. AG-181

    Agios

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. AG-236

    Agios

    Healthy Participants

    phase 1 small molecule active

    1 trial

  20. AG-348

    Agios

    Healthy

    phase 1 small molecule completed

    1 trial

  21. AG-348

    Agios

    Healthy Volunteer

    phase 1 small molecule completed

    2 trials

  22. AG-348

    Agios

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  23. AG-348

    Agios

    Sickle Cell Disease

    phase 1 small molecule completed

    1 trial

  24. AG-348 Sequence A

    Agios

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Drugs (3)

Search drugs →

  1. ivosidenib

    TIBSOVO

    ORAL approved

    L01XM02

  2. mitapivat

    PYRUKYND

    B06AX04

  3. mitapivat sulfate

    PYRUKYND

    ORAL approved

Patents (8)

Search patents →

  1. US 12428376

    Therapeutic compounds and compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12377093

    Pyruvate kinase activators for use in therapy

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11872225

    Pyruvate kinase modulators and use thereof

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11866411

    Therapeutic compounds and compositions

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Agios?

Agios (AGIO) is a pharma company. headquartered in CAMBRIDGE, MA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Agios sponsor?

We track 24 ClinicalTrials.gov-linked programs for Agios, including AG-348 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Agios company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.